Open Access Repository

Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence

Mills, L, Lintzeris, N, Bruno, R ORCID: 0000-0001-6673-833X, Montebello, M, Dunlop, A, Deacon, RM, Copeland, J, Jefferies, M, Rivas, C and Mammen, K 2020 , 'Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence' , Drug and Alcohol Review, vol. 39, no. 4 , pp. 356-364 , doi: 10.1111/dar.13050.

Full text not available from this repository.


Introduction and Aims:The Australian Treatment Outcomes Profile (ATOP) was developed as a clinical tool for monitoring the substance use, health and wellbeing of clients in alcohol and other drug treatment. This is the first psychometric validation of the ATOP in a cannabis-dependent treatment population. Design and Methods: A total of 128 individuals withcannabis dependence enrolled in an outpatient randomised controlled trial were administered the ATOP and gold-standardhealth and wellbeing questionnaires once by clinicians and once by researchers at baseline. Concurrent validity was assessed bytesting ATOP Psychological Health, Physical Health and Quality of Life questions against concurrently administered goldstandard questionnaires: the Short Form 36 Health Survey (SF-36), the 21-item Depression, Anxiety and Stress Scale(DASS-21) and the Sheehan Disability Scale (SDS). Interrater reliability was tested by comparing clinician-administeredATOP items at the medical screening interview to the same ATOP items administered by researchers at baseline. Results:ATOP Psychological Health showed moderate to strong correlations with SF-36 Mental Components, SF-36 Mental Healthand DASS-21 scores (r = 0.40–0.52) and ATOP Physical Health with SF-36 Physical Components and SF-36 GeneralHealth scores (r = 0.36–0.67). The ATOP Quality of Life scale showed moderate agreement with the SDS and sixdimensional health state short form scales (r = 0.38–0.40). ATOP substance use, employment, education and child care itemsshowed good to excellent interrater reliability (Krippendorff’s α = 0.62–0.81), and tobacco use, Psychological Health, Physical Health and Quality of Life showed fair to moderate interrater reliability (Krippendorff’s α = 0.42–0.53). Discussionand Conclusions. The ATOP appears to be valid and reliable when tested in a population with cannabis-dependence, justifying its widespread use in clinical settings.

Item Type: Article
Authors/Creators:Mills, L and Lintzeris, N and Bruno, R and Montebello, M and Dunlop, A and Deacon, RM and Copeland, J and Jefferies, M and Rivas, C and Mammen, K
Keywords: clinical outcome monitoring, health service evaluation, psychometric validation, cannabis dependence, addiction treatment
Journal or Publication Title: Drug and Alcohol Review
Publisher: Wiley-Blackwell Publishing Ltd.
ISSN: 0959-5236
DOI / ID Number: 10.1111/dar.13050
Copyright Information:

Copyright 2020 Australasian Professional Society on Alcohol and other Drugs

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page